Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Bank of New York Mellon Corp (BNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Bank of New York Mellon Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $352.08 (market cap $9.43B), while Bank of New York Mellon Corp trades at $162.9 (market cap $108.78B). The key difference: Bank of New York Mellon Corp is far larger — about 11.5× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bank of New York Mellon Corp pays a 1.38% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | BNY | |
|---|---|---|
Market Cap | $9.43B | $108.78B |
Sector | Health | Financials |
52-Week High | $356.25 | $162.35 |
52-Week Low | $241.71 | $101.00 |
Enterprise Value | $9.18B | — |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
BNY stock trades at $159.44, up 1.14% on the day, near the analyst consensus price target of $170.36. The stock shows a bullish technical trend with strong moving average signals, and fundamentals are robust with consistent earnings beats, revenue growth to $19.76B in 2025, and a net income margin of 29.96%. Recent news highlights strategic moves in digital asset infrastructure and a dividend declaration.
The outlook for BNY is positive, supported by earnings momentum and digital innovation, but risks include high investing cash outflows and interest expenses. Analyst sentiment is mixed with a slight hold bias, yet institutional upgrades and a strong ROE of 15.34% offer upside potential amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →
